A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naïve patients with chronic hepatitis C: ViSER1 results

Hepatology

Volumn 50, Issue 3, 2009, Pages 717-726

  Benhamou, Yves ^a   Afdhal, Nezam H ^b   Nelson, David R ^c   Shiffman, Mitchell L ^d   Halliman, Deanine G ^e   Heise, Jamie ^e   Chun, Eric ^e   Pockros, Paul J ^f  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^e Valeant Pharmaceuticals   (United States)

^f SCRIPPS CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN; TARIBAVIRIN; ALPHA2B INTERFERON; DRUG DERIVATIVE; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2B;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; ADOLESCENT; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; DOUBLE-BLIND METHOD; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN;

EID: 70349229380     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.23073     Document Type: Article

References (30)

1. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
2. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al., and the International Hepatitis Interventional Therapy Group. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.
3. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.HEPATOLOGY 2003;38:645-652.
4. Reddy KR, Shiffman ML, Morgan TR, Zeuzem S, Hadziyannis S, Hamzeh FM, et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007;5:124-129. (Pubitemid 46096836)
5. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype- 1-infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061-1069.
6. Sulkowski MS, Wasserman R, Brooks L, Ball L, Gish R. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepat 2004;11:243-250. (Pubitemid 38658449)
7. McHutchison JG, Manns MP, Longo DL. Definition and management of anemia in patients infected with hepatitis C virus. Liver Int 2006;26:389-398.
8. Sulkowski MS. Management of the hematologic complications of hepatitis C therapy. Clin Liver Dis 2005;9:601-616. (Pubitemid 41406390)
9. Younossi Z, Kallman J, Kincaid J. The effects of HCV infection and management on health-related quality of life. HEPATOLOGY 2007;45:806-816. (Pubitemid 46450632)
10. Liu WL, Su WC, Cheng CW, Hwang LH, Wang CC, Chen HL, et al. Ribavirin up-regulates the activity of double-stranded RNA-activated protein kinase and enhances the action of interferon-alpha against hepatitis C virus. J Infect Dis 2007;196:425-434.
11. Homma M, Matsuzaki Y, Inoue Y, Shibata M, Mitamura K, Tanaka N, et al. Marked elevation of erythrocyte ribavirin levels in interferon and ribavirin- induced anemia. Clin Gastroenterol Hepatol 2004;2:337-339. (Pubitemid 38447199)
12. Russmann S, Grattagliano I, Portincasa P, Palmieri VO, Palasciano G. Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research. Curr Med Chem 2006;13:3351-3357. (Pubitemid 44669779)
13. Kowdley KV. Hematologic side effects of interferon and ribavirin therapy. J Clin Gastroenterol 2005;39(1 Suppl.):S3-S8. (Pubitemid 40024231)
14. Wu JZ, Lin CC, Hong Z. Ribavirin, viramidine and adenosine-deaminase- catalysed drug activation: implication for nucleoside prodrug design. J Antimicrob Chemother 2003;52:543-546. (Pubitemid 37258410)
15. Lin C-C, Philips L, Xu C, Yeh L-T. Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers. J Clin Pharmacol 2004;44:265-275. (Pubitemid 38236158)
16. 14C]ribavirin in rat and monkey red blood cells and liver. Antimicrob Agents Chemother 2004;48:1872-1875.
17. Gish RG, Arora S, Reddy KR, Nelson DR, O'Brien C, Xu Y, et al. Virological response and safety outcomes in therapy-naive patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study. J Hepatol 2007;47:51-59. (Pubitemid 46817694)
18. Pockros PJ, Jacobson IM, Bacon BR, Afdhal NH, Poordad F, Chun E, et al. Taribavirin exposure analysis from a previous phase III trial correlates with phase IIb weight-based dosing interim results [Abstract].HEPATOLOGY 2008;48:1138A.
19. Benhamou Y, Pockros P, Rodriguez-Torres M, Gordon S, Shiffman M, Lurie Y, et al. The safety and efficacy of viramidine plus pegylated interferon alfa-2b versus ribavirin plus pegylated interferon alfa-2b in therapy-näve patients infected with HCV: phase 3 results (VISER1) [Abstract]. J Hepatol 2006;44(Suppl 2):S273.
20. Levin J. Viramidine phase III study-did not meet efficacy endpoint. Valeant looking at weight-based dosing of viramidine based on post-hoc analysis [NATAP conference report on Benhamou et al., J Hepatol 2006; 44(Suppl 2):S293.]. http://www.natap.org/2006/EASL/EASL-19.htm. Accessed May 2009.
21. Pockros P, Rodriguez-Torres M, Lurie Y, Gordon S, Shiffman M, Li Y, et al. Impact of taribavirin exposure on efficacy, anemia rates, and GI side effects when used with pegylated interferon alfa-2b for the treatment of chronic hepatitis C [Abstract]. J Hepatol 2007;46(Suppl):S239.
22. Jacobson I, Pockros P, Benhamou Y, Esteban-Mur R, Lurie Y, Flisiak R, et al. Impact of taribavirin and ribavirin exposure on efficacy and anemia rates when combined with pegylated interferon alfa-2b in the treatment of chronic HCV [Abstract]. HEPATOLOGY 2006;44:610A.
23. Jacobson IM, Brown RS Jr, Freilich B, Afdhal N, Kwo PY, Santoro J, et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. HEPATOLOGY 2007;46:971-981.
24. Benhamou Y. Anemia and clinical outcomes in hepatitis C. J Hepatol 2007;47:7-9.
25. Valeant Pharmaceuticals reports encouraging phase IIb results at treatment week 12 for taribavirin [press release]. Aliso Viejo, CA: Valeant Pharmaceuticals; updated March 17, 2008. http://www.valeant.com/mediaCenter/ newsArticle/newsArticle.jspf?objectId=4233. Accessed May 2009.
26. Pawlotsky J-M, Gish RG. Future therapies for hepatitis C. Antivir Ther 2006;11:397-408.
27. Keeffe EB. Future treatment of chronic hepatitis C. Antivir Ther 2007;12:1015-1025.
28. Pockros PJ. Emerging therapies for chronic hepatitis C virus. Gastroenterol Hepatol 2008;4:729-734.
29. McHutchison JG, Everson GT, Gordon SC, Jacobson I, Kauffman R, McNair L, et al. PROVE1: results from a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naive subjects with hepatitis C [Abstract]. J Hepatol 2008;48(Suppl 2):S4.
30. Kwo P, Lawitz E, McCone J, Schiff EG, Vierling J, Pound D, et al. Interim results from HCV SPRINT-1: RVR/EVR from phase 2 study of boceprevir plus PegIntron™ (peginterferon alfa-2b)/ribavirin in treatment-naive subjects with genotype-1 CHC [Abstract]. J Hepatol 2008;48(Suppl 2):S372.